Italia markets closed

Can-Fite BioPharma Ltd. (CANF)

NYSE American - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,2200-0,0400 (-1,77%)
Alla chiusura: 03:59PM EDT
2,2500 +0,03 (+1,35%)
Dopo ore: 06:26PM EDT

Can-Fite BioPharma Ltd.

10 Bareket Street
Kiryat Matalon PO Box 7537
Petah Tikva 4951778
Israel
972 3 924 1114
https://www.canfite.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno8

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Pnina Fishman Ph.D.Founder, Chief Scientific Officer & Executive Chairperson644kN/D1948
Mr. Motti FarbsteinCEO & Chief Operating and Financial Officer414kN/D1964
Dr. Sari Fishman Ph.D.Vice President of Business Development325kN/D1972
Dr. Ilan Cohn Ph.D.Co-Founder & DirectorN/DN/D1954
Dr. Stephen A. Harrison FACP, M.D.Member of Clinical Advisory Board & Consulting Chief Medical OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Governance aziendale

L'ISS Governance QualityScore di Can-Fite BioPharma Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.